Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.56 USD
Change Today -0.395 / -6.64%
Volume 7.8M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:21 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Open
$5.75
Previous Close
$5.95
Day High
$5.85
Day Low
$5.51
52 Week High
08/5/15 - $6.81
52 Week Low
12/23/14 - $1.26
Market Cap
1.3B
Average Volume 10 Days
7.0M
EPS TTM
$-0.99
Shares Outstanding
225.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

98 Employees
Last Reported Date: 03/2/15
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $755.2K
Executive Vice President and Chief Medical Of...
Total Annual Compensation: $513.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $407.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $380.8K
Senior Vice President of Finance and Controll...
Total Annual Compensation: $318.9K
Compensation as of Fiscal Year 2014.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Exelixis, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net product revenues of $7,992,000 compared to $6,562,000 a year ago. Loss from operations was $31,280,000 compared to $61,688,000 a year ago. Net loss was $43,362,000 or $0.22 per basic and diluted share compared to $73,410,000 or $0.38 per basic and diluted share a year ago. The decreased net loss for the quarter was primarily due to decreases in research and development expenses and selling, general and administrative expenses and an increase in product revenues. For the six months period, the company reported net product revenues of $17,380,000 compared to $11,467,000 a year ago. Loss from operations was $54,040,000 compared to $126,676,000 a year ago. Net loss was $78,532,000 or $0.40 per basic and diluted share compared to $148,029,000 or $0.77 per basic and diluted share a year ago.

Exelixis, Inc. to Report Q2, 2015 Results on Aug 11, 2015

Exelixis, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 11, 2015

Exelixis, Inc., Q2 2015 Earnings Call, Aug 11, 2015

Exelixis, Inc., Q2 2015 Earnings Call, Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $5.56 USD -0.395

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.12 USD -0.325
Array BioPharma Inc $5.76 USD -0.14
Curis Inc $2.53 USD -0.09
Cytokinetics Inc $6.92 USD 0.00
Evotec AG €3.65 EUR -0.105
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit www.exelixis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.